Teriparatide

Background

Teriparatide is a recombinant human parathyroid hormone (PTH) fragment corresponding to amino acids 1–34, representing the biologically active N‑terminal region of the 84‑amino‑acid endogenous hormone.[11] It was developed as an anabolic therapy for osteoporosis, in contrast to earlier antiresorptive agents such as bisphosphonates and denosumab.[1][11] Teriparatide (brand name Forteo in the United States and many other jurisdictions) was the first bone‑forming agent approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for osteoporosis in patients at high fracture risk.[11][12]

The concept of using PTH as an anabolic osteoporosis therapy emerged from animal studies demonstrating that intermittent low‑dose PTH increased bone mass, in contrast to continuous exposure which promoted bone resorption.[1][3] Early clinical development culminated in the pivotal Fracture Prevention Trial (FPT), after which teriparatide received regulatory approval for severe osteoporosis in postmenopausal women and men at high risk of fracture.[12]

In clinical practice, teriparatide is primarily used for severe osteoporosis (including glucocorticoid‑induced osteoporosis), and has also been explored for off‑label indications such as fracture healing, osteonecrosis of the jaw, and hypoparathyroidism.[11][13]

Mechanism of action

Receptor targets and signaling

Teriparatide is a selective agonist of the PTH type 1 receptor (PTH1R), a G protein‑coupled receptor expressed predominantly on osteoblasts, osteoblast precursors, and renal tubular cells.[1][3][11] Binding of PTH(1‑34) to PTH1R activates multiple intracellular signaling pathways:

• Gs/cAMP/PKA pathway, leading to increased expression of osteoblast survival and differentiation genes.[3][14]
• Gq/PLC/PKC pathways, including PKCδ‑dependent signaling implicated in osteogenic differentiation of human mesenchymal stem cells.[14]
• Downstream modulation of Wnt/β‑catenin signaling and other osteoanabolic pathways, with complex feedback from Wnt inhibitors such as sclerostin and DKK1.[3]

Intermittent vs continuous exposure

PTH is classically described as a catabolic hormone when exposure is continuous, enhancing bone resorption through osteoclast activation secondary to osteoblast-derived RANKL.[1][3] In contrast, once‑daily intermittent teriparatide preferentially stimulates osteoblast number and activity, increasing bone formation and bone turnover but with a net positive bone balance.[1][3][12] Proposed mechanisms for this preferential anabolic effect include:

• Stimulation of osteoblast progenitor recruitment and differentiation from mesenchymal stem cells.[14]
• Inhibition of osteoblast and osteocyte apoptosis.[3]
• A temporally limited “anabolic window” in which bone formation markers rise earlier and to a greater degree than resorption markers.[3][12]

Over time (after ~6–12 months), the magnitude of the anabolic response diminishes, likely due to osteoprogenitor depletion, remodeling dynamics, counter-regulatory molecules (e.g., Wnt inhibitors), and downstream desensitization of signaling pathways.[3]

Effects on bone and mineral metabolism

Key pharmacodynamic effects observed in humans include:

• Increased bone formation markers (e.g., serum P1NP) within weeks of initiation, followed later by increases in resorption markers (e.g., CTX).[3][12]
• Increased trabecular and cortical bone mass and improved microarchitecture, including increased trabecular thickness, connectivity, and cortical thickness, demonstrated in histomorphometry and imaging studies.[9][11][12]
• Transient increases in serum calcium due to stimulation of renal tubular calcium reabsorption and bone turnover.[1][12]

Evidence summary

Pivotal osteoporosis trials

Fracture Prevention Trial (FPT)

• Design: Randomized, double‑blind, placebo‑controlled trial in postmenopausal women with prior vertebral fractures.[12]
• Sample size: 1,637 women (teriparatide 20 or 40 µg vs placebo).[12]
• Outcomes: Daily 20 µg teriparatide for ~18 months significantly:
  • Reduced risk of new vertebral fractures by ~65% and nonvertebral fractures by ~53% vs placebo.[12]
  • Increased lumbar spine BMD by ~9–13% and femoral neck BMD by ~3–6%, dose‑dependent.[12]

Men with osteoporosis

• A randomized trial in 437 men with osteoporosis showed that daily 20 µg teriparatide increased lumbar spine BMD by ~5–6% and femoral neck BMD by ~1–2% over 11–18 months vs placebo.[12]

Glucocorticoid‑induced osteoporosis (GIOP)

• A randomized, double‑blind trial in 428 men and women on chronic glucocorticoids compared teriparatide 20 µg daily vs alendronate 10 mg daily.[12]
• Over 18 months, teriparatide produced greater lumbar spine BMD gains (7.2% vs 3.4%) and lower incidence of new vertebral fractures (0.6% vs 6.1%) than alendronate.[12]

Long‑term safety and extension data

An open‑label extension and postmarketing data provide 2.5 years of experience and beyond.[4][12]

• Neer et al. and subsequent cohorts confirmed sustained BMD gains that could be maintained or augmented by sequential antiresorptive therapy.[4][12]
• Postmarketing surveillance identified a signal for osteosarcoma in rats, but extensive epidemiologic follow‑up in humans has not shown an increased osteosarcoma incidence above background rates.[7][12]

Mechanistic and preclinical studies

• Animal models demonstrate that intermittent PTH(1‑34) increases trabecular bone mass and strength, whereas continuous infusion is catabolic.[1][3]
• Histomorphometric analyses in specific conditions (e.g., adynamic bone disease post‑parathyroidectomy) show marked increases in mineralized bone volume and remodeling after teriparatide therapy.[9]
• In vitro studies on human mesenchymal stem cells confirm that intermittent PTH(1‑34) enhances osteogenesis via PKCδ and associated pathways, supporting its anabolic mechanism.[14]

Indications beyond osteoporosis (largely off‑label)

A narrative and systematic review of teriparatide beyond osteoporosis summarizes case series and small studies in:

• Fracture healing and non‑unions: accelerated radiographic healing and improved outcomes in select high‑risk fractures.[11]
• Osteonecrosis of the jaw (ONJ): case reports describe resolution of bisphosphonate‑related ONJ following teriparatide therapy.[8][11]
• Dental implant stability and periodontal regeneration: early human and animal data suggest improved bone regeneration.[11][15]
• Hypoparathyroidism: small trials and case reports using PTH(1‑34) as replacement therapy, particularly where rhPTH(1‑84) is unavailable or ineffective.[11][13]

Evidence for these indications is limited to small trials, observational studies, and case reports, and remains investigational.[11][13]

Clinical and research uses

Approved uses (US/EU)

• Treatment of osteoporosis in postmenopausal women at high risk for fracture (history of osteoporotic fracture, multiple risk factors for fracture, or failure/intolerance of other osteoporosis therapy).[11][12]
• Treatment of osteoporosis in men at high risk for fracture.[11][12]
• Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in men and women at high fracture risk.[11][12]

Teriparatide is generally reserved for severe or very high‑risk osteoporosis, often followed by an antiresorptive agent to consolidate and maintain gains in BMD.[12]

Off‑label and investigational uses

Reported, largely off‑label, uses include:

• Promotion of fracture healing and treatment of delayed unions or non‑unions.[11]
• Management of osteonecrosis of the jaw, particularly bisphosphonate‑related ONJ, where case reports describe clinical and radiologic improvement.[8][11]
• Adjunctive therapy in chronic hypoparathyroidism, using multiple daily teriparatide injections when rhPTH(1‑84) is not available or inadequate.[13]
• Adynamic bone disease after parathyroidectomy, with case evidence of improved bone volume and remodeling.[9]
• Periodontal and dental applications, including enhancement of periodontal regeneration and implant osseointegration, currently at an experimental stage.[11][15]

Research directions include alternative delivery systems (e.g., orally administered robotic pill RT‑102), aiming to deliver PTH(1‑34) transenterically while reproducing subcutaneous pharmacokinetics.[6]

Dosing context

Teriparatide is administered as once‑daily subcutaneous injections.[1][11][12] Typical regimens in pivotal trials were:

• 20 µg once daily (the standard therapeutic dose in most clinical trials), injected into the thigh or abdominal wall.[12]
• Treatment duration in trials was generally 18–24 months, with an original lifetime treatment limit of 24 months based on rodent osteosarcoma findings.[4][12]

Pharmacokinetic characteristics include:

• Rapid absorption after subcutaneous injection, with peak plasma concentrations within ~30 minutes and an elimination half‑life of approximately 1 hour.[1][12]
• Short‑acting exposure consistent with the requirement for intermittent pharmacology to preserve anabolic predominance.[3]

Emerging formulations such as RT‑102, an orally administered robotic pill, aim to reproduce the exposure profile of subcutaneous teriparatide using transenteric injection; early phase studies indicate comparable PK/PD profiles but remain investigational.[6]

This section describes typical dosing used in trials and should not be interpreted as prescribing guidance.

Safety profile

Common adverse effects

Across randomized trials and postmarketing experience, commonly reported adverse events include:[1][4][12]

• Mild hypercalcemia, usually transient and asymptomatic, peaking 4–6 hours post‑dose.
• Nausea, vomiting, dizziness, and leg cramps.
• Injection site reactions (mild erythema or discomfort).

Transient orthostatic hypotension may occur shortly after injection, typically early in treatment, and patients in trials were often instructed to administer the dose while sitting or lying down.[1][12]

Osteosarcoma signal

Lifetime carcinogenicity studies in rats exposed to high doses of PTH(1‑34) for prolonged periods demonstrated an increased incidence of osteosarcoma, leading to initial strong warnings and a treatment‑duration restriction.[7][12]

Subsequent review of epidemiologic data and global postmarketing surveillance has not demonstrated an increased osteosarcoma incidence in humans above background rates.[7][12] Nonetheless, caution is maintained, particularly in patients with preexisting risk factors for osteosarcoma.

Other safety considerations

• Mild, reversible increases in urinary calcium have been observed, with rare reports of nephrolithiasis.[1][12]
• In patients with chronic kidney disease or adynamic bone disease, careful monitoring is required, and data remain limited.[9][12]
• Long‑term effects on extra‑skeletal tissues appear minimal, but the evidence base is still predominantly confined to 2–3 years of therapy + follow‑up.[4][12]

Regulatory status

United States

The US FDA has approved teriparatide (Forteo) for:[11][12]

• Postmenopausal women with osteoporosis at high risk for fracture.
• Men with primary or hypogonadal osteoporosis at high risk for fracture.
• Men and women with glucocorticoid‑induced osteoporosis at high risk for fracture.

Teriparatide initially carried a boxed warning for osteosarcoma and a lifetime treatment limit of 24 months, based on rat data.[7][12] Following reassessment of human safety data and osteosarcoma epidemiology, regulatory authorities have modified these warnings and restrictions, although use beyond 24 months is still generally reserved for exceptional circumstances and requires individualized risk–benefit assessment.[12]

European Union

The EMA similarly approved teriparatide for severe osteoporosis in postmenopausal women and men at increased fracture risk, and for glucocorticoid‑induced osteoporosis.[11][12] Full‑length PTH(1‑84) is also approved in the EU, resulting in some regional differences in the choice of PTH analog for specific indications (e.g., hypoparathyroidism), where PTH(1‑84) is preferred and teriparatide use is typically off‑label.[11][13]

Teriparatide remains under routine pharmacovigilance, with ongoing registry and postmarketing studies monitoring long‑term safety, fracture outcomes, and rare events such as osteosarcoma.[7][12]